Cryolife Inc  

(Public, NYSE:CRY)   Watch this stock  
Find more results for P. David Matthews
+0.22 (2.31%)
Real-time:   12:49PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 9.64 - 9.80
52 week 9.16 - 12.29
Open 9.64
Vol / Avg. 16,623.00/76,296.00
Mkt cap 271.63M
P/E 85.45
Div/yield 0.03/1.23
EPS 0.11
Shares 28.39M
Beta 1.19
Inst. own 62%
Oct 26, 2015
Q3 2015 CryoLife Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 12, 2015
CryoLife Inc at Canaccord Genuity Growth Conference
Jul 28, 2015
Q2 2015 CryoLife Inc Earnings Call - Webcast
Jul 28, 2015
Q2 2015 CryoLife Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1.41% 5.06%
Operating margin -1.29% 6.11%
EBITD margin - 10.28%
Return on average assets -1.15% 4.17%
Return on average equity -1.32% 4.88%
Employees 535 -
CDP Score - -


1655 Roberts Blvd NW
KENNESAW, GA 30144-3632
United States - Map
+1-770-4193355 (Phone)
+1-770-4260031 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CryoLife, Inc. (CryoLife) is a medical device company. The Company is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, HeRO Graft, and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company's product BioGlue, is a polymer consisting of bovine blood protein and an agent for cross-linking proteins, which was developed for use in cardiac, vascular, pulmonary, and surgical applications. The Company developed BioFoam to seal organs, such as the liver, and for use in cardiovascular surgeries, and provide hemostasis in penetrating wounds and trauma.

Officers and directors

James Patrick Mackin Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
D. Ashley Lee CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
David P. Lang Senior Vice President - International Sales and Marketing
Age: 68
Bio & Compensation  - Reuters
William Matthews Senior Vice President - Operations, Quality, and Regulatory
Bio & Compensation  - Reuters
Jean F. Holloway Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Bruce G. Anderson Vice President - U.S. Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Scott B. Capps Vice President - Clinical Research
Age: 48
Bio & Compensation  - Reuters
David C. Gale Ph.D. Vice President - Research & Development
Age: 47
Bio & Compensation  - Reuters
Jon W. Salveson Director
Age: 50
Bio & Compensation  - Reuters
Thomas F. Ackerman Independent Director
Age: 60
Bio & Compensation  - Reuters